/
Oncology
Glioblastoma Multiforme
22
Pipeline Programs↗
33
Active Trials↗
36
Companies Involved↗
Glioblastoma Multiforme is an emerging landscape with 22 programs across 36 companies. The most active players are Johnson & Johnson, CNS Pharmaceuticals, Inc., Acerta Pharma BV. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 17
Phase 29
Approved
No programs
Analysis
Modality Breakdown
88%
Small molecule
15 of 17 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 95% of 22 pipeline programs.
Analysis
Trial Status
290
clinical trials
Completed172 · 59%
Terminated42 · 14%
Unknown status31 · 11%
Recruiting18 · 6%
Active, not recruiting15 · 5%
Withdrawn10 · 3%
Other2 · 1%
Clinical Trials
Trial Activity
290 trials
Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study
Recruiting·—·N/A·NCT06954636·128 enrolled
Page 1 of 20
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)